Brought to you by 
Juno and MedImmune enter non-Hodgkin's lymphoma clinical trial collaboration
11 Oct 2021
Executive Summary
Juno Therapeutics Inc. and MedImmune LLC will work together on a clinical trial evaluating the combination of one of Juno's CD19-direted chimeric antigen receptor (CAR) T-cell candidates together with MedImmune's PD-L1 inhibitor durvalumab (MEDI4736). The study will focus on safety and efficacy of the combination as a treatment for non-Hodgkin's lymphoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Juno and MedImmune enter non-Hodgkin's lymphoma clinical trial collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice